Free Trial

Organovo (ONVO) Competitors

Organovo logo

ONVO vs. MEIP, PRPH, GELS, ME, RLMD, TRIB, SYBX, ERNA, MRKR, and CLDI

Should you be buying Organovo stock or one of its competitors? The main competitors of Organovo include MEI Pharma (MEIP), ProPhase Labs (PRPH), Gelteq (GELS), 23andMe (ME), Relmada Therapeutics (RLMD), Trinity Biotech (TRIB), Synlogic (SYBX), Eterna Therapeutics (ERNA), Marker Therapeutics (MRKR), and Calidi Biotherapeutics (CLDI). These companies are all part of the "pharmaceutical products" industry.

Organovo vs.

MEI Pharma (NASDAQ:MEIP) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings.

MEI Pharma received 227 more outperform votes than Organovo when rated by MarketBeat users. Likewise, 63.32% of users gave MEI Pharma an outperform vote while only 45.37% of users gave Organovo an outperform vote.

CompanyUnderperformOutperform
MEI PharmaOutperform Votes
423
63.32%
Underperform Votes
245
36.68%
OrganovoOutperform Votes
196
45.37%
Underperform Votes
236
54.63%

In the previous week, Organovo had 2 more articles in the media than MEI Pharma. MarketBeat recorded 2 mentions for Organovo and 0 mentions for MEI Pharma. MEI Pharma's average media sentiment score of 0.00 beat Organovo's score of -0.10 indicating that MEI Pharma is being referred to more favorably in the media.

Company Overall Sentiment
MEI Pharma Neutral
Organovo Neutral

52.4% of MEI Pharma shares are owned by institutional investors. Comparatively, 8.2% of Organovo shares are owned by institutional investors. 3.1% of MEI Pharma shares are owned by insiders. Comparatively, 3.7% of Organovo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Given Organovo's higher probable upside, analysts clearly believe Organovo is more favorable than MEI Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MEI Pharma
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Organovo
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

MEI Pharma has a net margin of 0.00% compared to Organovo's net margin of -10,151.64%. MEI Pharma's return on equity of -84.92% beat Organovo's return on equity.

Company Net Margins Return on Equity Return on Assets
MEI PharmaN/A -84.92% -67.53%
Organovo -10,151.64%-346.26%-187.53%

MEI Pharma has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, Organovo has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.

MEI Pharma has higher revenue and earnings than Organovo. MEI Pharma is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MEI Pharma$65.30M0.22$17.78M-$4.75-0.45
Organovo$122K0.00-$14.67M-$10.20N/A

Summary

MEI Pharma beats Organovo on 12 of the 16 factors compared between the two stocks.

Get Organovo News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONVO vs. The Competition

MetricOrganovoBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$3.47M$2.93B$5.33B$8.39B
Dividend YieldN/A1.63%5.21%4.10%
P/E Ratio-2.4031.1826.7519.70
Price / SalesN/A398.78392.04122.35
Price / CashN/A168.6838.2534.62
Price / BookN/A3.236.774.50
Net Income-$14.67M-$72.35M$3.23B$248.22M

Organovo Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONVO
Organovo
N/AN/AN/AN/A$3.47M$122,000.00-2.4020Upcoming Earnings
Gap Up
MEIP
MEI Pharma
2.1836 of 5 stars
$2.08
+1.3%
N/A-31.0%$13.83M$65.30M-0.36100
PRPH
ProPhase Labs
1.8261 of 5 stars
$0.33
+7.9%
N/A-94.1%$13.69M$6.77M-0.26130Earnings Report
Gap Down
GELS
Gelteq
N/A$1.44
+5.1%
N/AN/A$13.59MN/A0.00N/APositive News
ME
23andMe
N/A$0.50
-35.3%
N/A-95.2%$13.36M$208.78M-0.03770Gap Down
High Trading Volume
RLMD
Relmada Therapeutics
4.4302 of 5 stars
$0.40
-4.6%
$4.25
+962.5%
-80.1%$13.28MN/A-0.1410Positive News
Insider Trade
Gap Down
TRIB
Trinity Biotech
0.7127 of 5 stars
$0.73
-3.1%
N/A-52.6%$13.18M$59.13M-0.32480Gap Down
SYBX
Synlogic
N/A$1.13
+0.9%
N/A-30.4%$13.10M$8,000.00-0.2780Gap Up
High Trading Volume
ERNA
Eterna Therapeutics
0.7563 of 5 stars
$0.21
+5.2%
N/A-88.5%$13.10M$582,000.00-0.0310Gap Up
MRKR
Marker Therapeutics
4.0871 of 5 stars
$1.14
-1.7%
$13.17
+1,055.0%
-71.3%$12.90M$6.59M-0.9560Positive News
CLDI
Calidi Biotherapeutics
1.9147 of 5 stars
$0.44
-3.3%
$15.00
+3,279.9%
N/A$12.63M$50,000.000.0038Gap Down

Related Companies and Tools


This page (NASDAQ:ONVO) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners